In mouse models of glioma and hepatocellular carcinoma, Fgl2 from the tumor conferred cancer cells with stem-like qualities (36), inhibited CD103+ dendritic cell maturation (32, 37), and skewed myeloid cells to a protumorigenic state (35, 39). This evidence concerns the gene FGL2 and central nervous system cancer.